The Contract Biomanufacturing Market Outlook to 2017$5,000.00
The biologic drug market is growing at nearly twice the pace of the overall pharmaceutical market, driven by major therapeutic fields under research such as oncology and autoimmune diseases. The forecasted 20% annual increase in biologic active pharmaceutical ingredient (API) demand between 2011 and 2017 combined with the growth of biosimilars will generate a positive environment for the biologics contract manufacturing organization (CMO) market to grow at 9% per year over the same period.November 3, 2016
Leading Players in the CMO Market$5,000.00
he following companies are the 10 largest small-molecule contract manufacturing organizations (CMOs) by revenue. While many of the firms also contain biologics businesses, where possible only the relevant small-molecule revenues have been counted.November 3, 2016
CMOs in China and India: Still the Places to be?$5,000.00
Low-cost and skilled workforces in China and India have positioned both countries as increasingly important manufacturing hubs for pharmaceutical companies, as they seek to contain costs while retaining quality outsourcing partners.
Despite the apparent inevitability of the contract manufacturing organization (CMO) sector’s growth in China and India, a recent wave of scandals has put significant dents in the reputations of both countries as locations for foreign firms to manufacture drugs. Rising costs have also caused some firms to question whether using one of the region’s many CMOs is worth the risk.November 3, 2016